S.Amdt. 1271Senate118th Congress (2023-2025)2nd degree

S.Amdt. 1271

Submitted September 20, 2023

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
Floor Latest Action

Senate amendment submitted

September 20, 2023

View full timeline
Floor

Senate amendment submitted

September 20, 2023

Floor

Senate amendment submitted

September 20, 2023

Text

Submitted

SA 1271. Ms. SINEMA submitted an amendment intended to be proposed to
amendment SA 1092 proposed by Mrs. Murray (for herself and Ms. Collins)
to the bill H.R. 4366, making appropriations for military construction,
the Department of Veterans Affairs, and related agencies for the fiscal
year ending September 30, 2024, and for other purposes; which was
ordered to lie on the table; as follows:

At the appropriate place in division A, insert the
following:

SEC. ___. REPORT ON FEASIBILITY OF STUDY BY DEPARTMENT OF
VETERANS AFFAIRS ON PATIENT RESPONSES TO
PHARMACEUTICALS BASED ON THEIR GENETIC PROFILE.

(a) In General.--Not later than 90 days after the date of
the enactment of this Act, the Secretary of Veterans Affairs
shall submit to the appropriate committees of Congress a
report on the feasibility, advisability, and cost estimate of
undertaking a study to record patient responses to
pharmaceuticals based on their genetic profile, which shall
include the elements specified under subsection (b).
(b) Elements of Study.--The elements specified under this
subsection are--
(1) providing a patient with a pharmacogenomics test;
(2) using the results of that test, through an integrated
application programming interface platform, and mapping those
results against--
(A) the medical condition or conditions of the patient;
(B) the medications currently prescribed to the patient;
and
(C) different therapeutics or medications that are widely
prescribed to treat such condition or conditions;
(3) providing the treating physician of the patient with
easily understood, actionable, digitized information to
utilize in making a decision about the course of medication
or medications that would yield the greatest benefit to the
patient and limit the risk of potential harm or adverse
events based upon identified drug-to-gene and drug-to-drug
interactions; and
(4) including an analysis on cost saving to the Department
of Veterans Affairs and the patient.
(c) Appropriate Committees of Congress Defined.--In this
section, the term ``appropriate committees of Congress''
means--
(1) the Committee on Appropriations and the Committee on
Veterans' Affairs of the Senate; and
(2) the Committee on Appropriations and the Committee on
Veterans' Affairs of the House of Representatives.
______